辛伐他汀联合非诺贝特治疗高脂血症50例疗效评价

Evaluation on the Effect of Simvastatin Combined with Fenofibrate in Treating of Hyperlipidemia on 50 Cases

目的探讨辛伐他汀联合非诺贝特治疗高脂血症的疗效及安全性,为临床高脂血症的治疗提供用药参考。方法选取2011年1月至2014年1月收治的100例高脂血症患者,随机分为两组。A组(50例)睡前服用辛伐他汀10 mg,B组(50例)在此基础上于早、午各口服非诺贝特100 mg。连续治疗8周后比较两组患者调脂效果和不良反应。结果两组患者治疗8周后,血脂水平均有改善,但B组的总胆固醇(TC)、三酰甘油(TG)水平均明显低于A组,血清高密度脂蛋白胆固醇(HDL-C)水平均明显高于A组(P<0.05);B组的降TC有效率及升HDL-C有效率均高于A组,但不良反应发生率与A组比较,差异无统计学意义(P>0.05)。结论辛伐他汀联合非诺贝特治疗高脂血症疗效可靠,安全性良好。

Objective To observe the efficacy and safety of simvastatin combined with fenofibrate in treating hyperlipidemia to provide reference for the clinical treatment of hyperlipidemia. Methods 100 cases of hyperlipidemia from January 2011 to January 2014 were selected as the research subjects and randomly divided into two groups. Group A（ 50 cases） took 10 mg of simvastatin before sleep,while group B（ 50 cases） took 10 mg of simvastatin with additional oral 100 mg of fenofibrate in the morning and at noon. The lipid regulating effect and adverse reactions after 8 weeks of continuous treatment were compared between the two groups. Results The blood lipid levels after 8-week treatment in the two groups were improved,but the total cholesterol and triglyceride in group B were significantly lower than those in group A,and the serum high density lipoprotein cholesterol（ HDL-C） level was significantly higher than that in group A with statistically significant difference（ P 0. 05）; the incidence of adverse reactions had no statistically significant difference compared with group A（ P 0. 05）. Conclusion Simvastatin plus fenofibrate has reliable effect and good safety for treating hyperlipidemia.